FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1977392502> ?p ?o ?g. }

• W1977392502 endingPage "593" @default.
• W1977392502 startingPage "588" @default.
• W1977392502 abstract "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity." @default.
• W1977392502 created "2016-06-24" @default.
• W1977392502 creator A5004126746 @default.
• W1977392502 creator A5020555628 @default.
• W1977392502 creator A5025848771 @default.
• W1977392502 creator A5028078923 @default.
• W1977392502 creator A5035482209 @default.
• W1977392502 creator A5040044145 @default.
• W1977392502 creator A5046264008 @default.
• W1977392502 creator A5047879448 @default.
• W1977392502 creator A5048649057 @default.
• W1977392502 creator A5051858382 @default.
• W1977392502 creator A5056231722 @default.
• W1977392502 creator A5057371623 @default.
• W1977392502 creator A5057962993 @default.
• W1977392502 creator A5061676019 @default.
• W1977392502 creator A5068994340 @default.
• W1977392502 creator A5069952026 @default.
• W1977392502 creator A5070567202 @default.
• W1977392502 creator A5071468635 @default.
• W1977392502 creator A5076177583 @default.
• W1977392502 creator A5084157591 @default.
• W1977392502 creator A5085252648 @default.
• W1977392502 creator A5087016134 @default.
• W1977392502 date "2000-09-01" @default.
• W1977392502 modified "2023-10-15" @default.
• W1977392502 title "A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse" @default.
• W1977392502 cites W1498193719 @default.
• W1977392502 cites W1564678394 @default.
• W1977392502 cites W1583848026 @default.
• W1977392502 cites W1828405036 @default.
• W1977392502 cites W1835101589 @default.
• W1977392502 cites W1861898234 @default.
• W1977392502 cites W1947168884 @default.
• W1977392502 cites W1965397926 @default.
• W1977392502 cites W1973027090 @default.
• W1977392502 cites W1982792079 @default.
• W1977392502 cites W1993808515 @default.
• W1977392502 cites W2033433258 @default.
• W1977392502 cites W2038835567 @default.
• W1977392502 cites W2043451385 @default.
• W1977392502 cites W2061554178 @default.
• W1977392502 cites W2065634769 @default.
• W1977392502 cites W2079786467 @default.
• W1977392502 cites W2086167722 @default.
• W1977392502 cites W2088925558 @default.
• W1977392502 cites W2109549713 @default.
• W1977392502 cites W2167571044 @default.
• W1977392502 cites W2407969405 @default.
• W1977392502 cites W28499524 @default.
• W1977392502 doi "https://doi.org/10.1054/bjoc.2000.1316" @default.
• W1977392502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2363506" @default.
• W1977392502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10944597" @default.
• W1977392502 hasPublicationYear "2000" @default.
• W1977392502 type Work @default.
• W1977392502 sameAs 1977392502 @default.
• W1977392502 citedByCount "862" @default.
• W1977392502 countsByYear W19773925022012 @default.
• W1977392502 countsByYear W19773925022013 @default.
• W1977392502 countsByYear W19773925022014 @default.
• W1977392502 countsByYear W19773925022015 @default.
• W1977392502 countsByYear W19773925022016 @default.
• W1977392502 countsByYear W19773925022017 @default.
• W1977392502 countsByYear W19773925022018 @default.
• W1977392502 countsByYear W19773925022019 @default.
• W1977392502 countsByYear W19773925022020 @default.
• W1977392502 countsByYear W19773925022021 @default.
• W1977392502 countsByYear W19773925022022 @default.
• W1977392502 countsByYear W19773925022023 @default.
• W1977392502 crossrefType "journal-article" @default.
• W1977392502 hasAuthorship W1977392502A5004126746 @default.
• W1977392502 hasAuthorship W1977392502A5020555628 @default.
• W1977392502 hasAuthorship W1977392502A5025848771 @default.
• W1977392502 hasAuthorship W1977392502A5028078923 @default.
• W1977392502 hasAuthorship W1977392502A5035482209 @default.
• W1977392502 hasAuthorship W1977392502A5040044145 @default.
• W1977392502 hasAuthorship W1977392502A5046264008 @default.
• W1977392502 hasAuthorship W1977392502A5047879448 @default.
• W1977392502 hasAuthorship W1977392502A5048649057 @default.
• W1977392502 hasAuthorship W1977392502A5051858382 @default.
• W1977392502 hasAuthorship W1977392502A5056231722 @default.
• W1977392502 hasAuthorship W1977392502A5057371623 @default.
• W1977392502 hasAuthorship W1977392502A5057962993 @default.
• W1977392502 hasAuthorship W1977392502A5061676019 @default.
• W1977392502 hasAuthorship W1977392502A5068994340 @default.
• W1977392502 hasAuthorship W1977392502A5069952026 @default.
• W1977392502 hasAuthorship W1977392502A5070567202 @default.
• W1977392502 hasAuthorship W1977392502A5071468635 @default.
• W1977392502 hasAuthorship W1977392502A5076177583 @default.
• W1977392502 hasAuthorship W1977392502A5084157591 @default.
• W1977392502 hasAuthorship W1977392502A5085252648 @default.
• W1977392502 hasAuthorship W1977392502A5087016134 @default.
• W1977392502 hasBestOaLocation W19773925021 @default.
• W1977392502 hasConcept C121608353 @default.
• W1977392502 hasConcept C126322002 @default.
• W1977392502 hasConcept C141071460 @default.
• W1977392502 hasConcept C143998085 @default.
• W1977392502 hasConcept C159110408 @default.

• next